Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug;7(5):518-522.
doi: 10.1016/j.jaccao.2025.05.014.

Current Insights in Bidirectional Cardio-Oncology: Heart Failure Driving Cancer: JACC: CardioOncology Short-Form Primer

Rudolf A de Boer  1 , Laura I Yousif  2 , Joseph Pierre Aboumsallem  2 , Wouter C Meijers  2
Affiliations
Free article
Review

Current Insights in Bidirectional Cardio-Oncology: Heart Failure Driving Cancer: JACC: CardioOncology Short-Form Primer

Rudolf A de Boer et al. JACC CardioOncol. 2025 Aug.
Free article
No abstract available

Keywords: cancer; cardiovascular disease; heart failure; mechanisms; reverse cardio-oncology; risk factor; underlying mechanisms.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr de Boer is supported by the Netherlands Heart Foundation (grants 2020B005 and 01-003-2022-0358), a Netherlands Heart Foundation grant cofunded by ERA4Health (GA grant 101095426 of the European Union Horizon Europe Research and Innovation Programme), and the European Research Council (CoG 818715). Dr Meijers is supported by grants from the Dutch Heart Foundation (Dekkerbeurs 03-005-2021-T005) and ZonMw (Off Road [04510012210034] and NWO-VENI [09150162310159]). The institution of Dr de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol Myers Squibb, Novo Nordisk, and Roche. Dr de Boer has had speaker engagements with, received fees from, and/or served on advisory boards for Abbott, AstraZeneca, Bristol Myers Squibb, Novo Nordisk, Roche, and Zoll; and has received travel support from Abbott and Novo Nordisk. Dr Meijers has received speaker and advisory board fees from Daiichi-Sankyo and Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Similar articles

See all similar articles

LinkOut - more resources